NASDAQ:GRI GRI Bio (GRI) Stock Price, News & Analysis $1.40 +0.01 (+0.72%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GRI Bio Stock (NASDAQ:GRI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GRI Bio alerts:Sign Up Key Stats Today's Range$1.35▼$1.4350-Day Range$1.17▼$2.1452-Week Range$1.10▼$30.43Volume83,980 shsAverage Volume225,935 shsMarket Capitalization$3.53 millionP/E RatioN/ADividend YieldN/APrice Target$22.00Consensus RatingBuy Company Overview GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California. Read More GRI Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreGRI MarketRank™: GRI Bio scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGRI Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGRI Bio has only been the subject of 2 research reports in the past 90 days.Read more about GRI Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GRI Bio are expected to grow in the coming year, from ($3.04) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GRI Bio is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GRI Bio is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGRI Bio has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.13% of the float of GRI Bio has been sold short.Short Interest Ratio / Days to CoverGRI Bio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GRI Bio has recently increased by 38.25%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGRI Bio does not currently pay a dividend.Dividend GrowthGRI Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.13% of the float of GRI Bio has been sold short.Short Interest Ratio / Days to CoverGRI Bio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GRI Bio has recently increased by 38.25%, indicating that investor sentiment is decreasing significantly. News and Social Media1.5 / 5News SentimentN/A News SentimentGRI Bio has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for GRI Bio this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added GRI Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GRI Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.87% of the stock of GRI Bio is held by insiders.Percentage Held by InstitutionsOnly 33.95% of the stock of GRI Bio is held by institutions.Read more about GRI Bio's insider trading history. Receive GRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GRI Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GRI Stock News HeadlinesGRI Bio (NASDAQ:GRI) Shares Up 2.1% - What's Next?August 21 at 4:27 AM | americanbankingnews.comGRI Bio Stockholders Approve Equity Plan AmendmentAugust 14, 2025 | msn.comTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again … | Weiss Ratings (Ad)GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechAugust 14, 2025 | globenewswire.comGRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)July 31, 2025 | finance.yahoo.comGRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” SegmentJuly 31, 2025 | globenewswire.comGRI Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceJuly 24, 2025 | finance.yahoo.comGRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | globenewswire.comSee More Headlines GRI Stock Analysis - Frequently Asked Questions How have GRI shares performed this year? GRI Bio's stock was trading at $14.0828 at the beginning of 2025. Since then, GRI shares have decreased by 90.1% and is now trading at $1.40. How were GRI Bio's earnings last quarter? GRI Bio, Inc. (NASDAQ:GRI) announced its quarterly earnings data on Thursday, August, 14th. The company reported ($1.31) EPS for the quarter, meeting the consensus estimate of ($1.31). When did GRI Bio's stock split? Shares of GRI Bio reverse split on Monday, February 24th 2025.The 1-17 reverse split was announced on Wednesday, February 19th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. How do I buy shares of GRI Bio? Shares of GRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GRI Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that GRI Bio investors own include SoFi Technologies (SOFI), NuCana (NCNA), Caribou Biosciences (CRBU), Cardio Diagnostics (CDIO), Intrusion (INTZ), Lonestar Resources US (LONE) and Children's Place (PLCE). Company Calendar Last Earnings8/14/2025Today8/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GRI CIK1824293 Webwww.vallon-pharma.com Phone267-607-8255FaxN/AEmployees1Year FoundedN/APrice Target and Rating Average Price Target for GRI Bio$22.00 High Price Target$34.00 Low Price Target$10.00 Potential Upside/Downside+1,471.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($11.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-327.62% Return on Assets-191.40% Debt Debt-to-Equity RatioN/A Current Ratio2.41 Quick Ratio1.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / Book1.06Miscellaneous Outstanding Shares2,515,000Free Float2,493,000Market Cap$3.52 million OptionableNot Optionable Beta-1.61 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:GRI) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRI Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.